Related Experiment Video
Updated: Sep 20, 2025
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
660
Emerging Approaches for Enabling RNAi Therapeutics
Argha M Mallick1, Archana Tripathi1, Sukumar Mishra1
1Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, 741246, India.
Chemistry, an Asian Journal
|June 11, 2022
Summary
RNA interference (RNAi) therapeutics, using small interfering RNA (siRNA), require efficient delivery vehicles. This review explores designing principles and examples of these vehicles for genetic diseases and cancer therapy.
Area of Science:
- Biotechnology
- Molecular Biology
- Genetics
Background:
- RNA interference (RNAi) is an evolutionary mechanism for defense against foreign genetic material.
- Small interfering RNA (siRNA) offers therapeutic potential for gene silencing.
- Effective delivery of siRNA is crucial for its therapeutic efficacy, requiring vehicles to overcome physiological barriers and reach the RISC complex.
Purpose of the Study:
- To review the design principles and examples of delivery vehicles for RNAi therapeutics.
- To discuss the applications of RNAi therapeutics in genetic diseases, epigenetic modifications, and cancer therapy.
- To explore strategies and opportunities for developing clinically translatable RNAi delivery vehicles.
Main Methods:
- Literature review of existing research on RNAi delivery vehicles.
- Analysis of designing principles for various classes of delivery systems.
- Discussion of therapeutic applications and future directions in RNAi delivery.
Main Results:
- Various classes of delivery vehicles have demonstrated efficiency in RNAi therapeutics.
- RNAi holds promise for treating genetic disorders, epigenetic modifications, and enabling personalized cancer therapy.
- Significant progress has been made in developing strategies for efficient siRNA delivery.
Conclusions:
- Efficient delivery vehicles are essential for realizing the full therapeutic potential of siRNA.
- Continued research into delivery systems is critical for advancing RNAi-based treatments for various diseases.
- Translating these advancements into clinical practice requires innovative strategies and further development.
Related Concept Videos
02:15Experimental RNAi
6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K
01:20Types of RNA
6.6K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
6.6K
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
01:29Translational Regulation
114
Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
114
01:29Microorganisms in Medicine and Therapeutics
384
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
384